After a @-week lipid-stabilization period , patients ( n = @ ) were randomized to compare evolocumab ( @ mg every @ weeks or @ mg monthly ) with placebo ( every @ weeks or monthly ) or ezetimibe ( @ mg or placebo daily ; atorvastatin patients only ) when added to statin therapies .